Loading...
Market
How will Abiologics' first Syntein™ drug be administered by December 31, 2024?
2
Resolution / Starting Odds
Oral • 25%
Injection • 25%
Topical • 25%
Other • 25%
Official press release or announcement from Abiologics
Story
Flagship Pioneer Launches Abiologics, Founded by Noubar Afeyan, to Develop Synteins™ Using AI and High Throughput Chemical Protein Synthesis
Jul 23, 2024, 12:22 PM
Flagship Pioneer's new venture, Abiologics, aims to revolutionize the field of therapeutics by developing a new class of programmable medicines known as Synteins™. Utilizing generative artificial intelligence and high-throughput chemical protein synthesis, Abiologics seeks to create supranatural biologics that can overcome the limitations of existing medicines. The company, founded by Noubar Afeyan, focuses on designing biologics composed of artificial building blocks at scale, with the goal of providing life-changing treatments to patients. This initiative marks a significant advancement in the drug development landscape, addressing challenges related to usability, administration routes, and tolerability of current biologics and protein drugs.
View original story
Similar markets
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Yes • 50%
No • 50%
Approved • 25%
Rejected • 25%
Request for more data • 25%
Other • 25%
Yes • 50%
No • 50%
Respiratory drug • 25%
Immunology drug • 25%
Vaccine • 25%
Other • 25%
Adaptimmune (Afami-cel) • 25%
Checkpoint Therapeutics (Cosibelimab) • 25%
Mirati Therapeutics (Adagrasib-Cetuximab) • 25%
Other • 25%
Yes • 50%
No • 50%
Significant efficacy • 25%
Moderate efficacy • 25%
No efficacy • 25%
Inconclusive results • 25%
Approved by FDA • 25%
Approved by EMA • 25%
Approved by another regulatory body • 25%
Not approved by any major regulatory body • 25%